Compare Novo Nordisk A/S (NVO) vs Block Inc (XYZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Block Inc — how do they compare? Novo Nordisk A/S trades at $49.32 (market cap $220.53B), while Block Inc trades at $80.35 (market cap $47.19B). The key difference: Novo Nordisk A/S is far larger — about 4.7× Block Inc's market cap, and Novo Nordisk A/S pays a 3.63% dividend while Block Inc pays none. Which is the better fit depends on your goals.
| NVO | XYZ | |
|---|---|---|
Market Cap | $220.53B | $47.19B |
Sector | Health | Technology |
52-Week High | $71.70 | $81.81 |
52-Week Low | $35.29 | $49.04 |
Enterprise Value | $239.49B | $42.06B |
Dividend Yield | 3.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XYZ trades at $80.38, up 0.55% today, with a bullish technical signal and strong analyst consensus. Recent Q1 2026 earnings beat expectations, but net income margin fell to 3.3% in 2025. The stock is supported by positive sentiment from Zacks upgrades and momentum coverage, though it faces risks from a recent $45 million settlement and mixed cash flow trends.
The outlook is cautiously optimistic, with a consensus price target of $89.64 offering ~12% upside. Key opportunities include earnings growth and Cash App strength, but risks involve credit losses, regulatory scrutiny, and a high P/E ratio of 61.95. Institutional selling and insider sales add near-term pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Block Inc
Founded in 2009, Block provides payment acquiring services to merchants, along with related services. The company also launched Cash App, a person-to-person payment network. Block has operations in Canada, Japan, Australia, and the United Kingdom
Read more on XYZ →
